Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Cariprazine, a dopamine D3/D2 receptor partial agonist with preference for D3 receptors, has demonstrated efficacy in randomized controlled trials in schizophrenia. This multinational, randomized, double-blind, placebo-controlled, parallel-group study evaluated the efficacy, safety, and tolerability of cariprazine for relapse prevention in adults with schizophrenia; total study duration was up to 97weeks. Schizophrenia symptoms were treated/stabilized with cariprazine 3-9mg/d during 20-week open-label treatment consisting of an 8-week, flexible-dose run-in phase and a 12-week fixed-dose stabilization phase. Stable patients who completed open-label treatment could be randomized to continued cariprazine (3, 6, or 9mg/d) or placebo for double-blind treatment (up to 72weeks). The primary efficacy parameter was time to relapse (worsening of symptom scores, psychiatric hospitalization, aggressive/violent behavior, or suicidal risk); clinical measures were implemented to ensure safety in case of impending relapse. A total of 264/765 patients completed open-label treatment; 200 eligible patients were randomized to double-blind placebo (n=99) or cariprazine (n=101). Time to relapse was significantly longer in cariprazine- versus placebo-treated patients (P=.0010, log-rank test). Relapse occurred in 24.8% of cariprazine- and 47.5% of placebo-treated patients (hazard ratio [95% CI]=0.45 [0.28, 0.73]). Akathisia (19.2%), insomnia (14.4%), and headache (12.0%) were reported in ≥10% of patients during open-label treatment; there were no cariprazine adverse events ≥10% during double-blind treatment. Long-term cariprazine treatment was significantly more effective than placebo for relapse prevention in patients with schizophrenia. The long-term safety profile in this study was consistent with the safety profile observed in previous cariprazine clinical trials. ClincalTrials.gov identifier: NCT01412060.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 3×
“Suicidal ideation and behavior According to Columbia-Suicide Severity Rating Scale (C-SSRS) (Posner et al., 2011) findings, suicidal ideation was reported in 29 (3.”
MethodInfluentialDiscovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101004323.x · Cited by 1,097 · cited 2×
“At the end of open-label treatment, mean improvements in PANSS total and subscale scores, CGI-S, NSA-16 total, and PSP scores were observed; at the end of double-blind treatment, scores on these scales worsened to a greater extent for placebo-treated patients than for cariprazine-treated patients (Table 3). on): ≥10-p…”
BackgroundLeucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · cited 1×
“…results, estimated relapse rates in a meta-analysis evaluating 1-year relapse in schizophrenia were 27% and 64% for antipsychotic drugs and placebo, respectively (Leucht et al., 2012); the analyses included both oral and depot agents, and depot preparations reduced relapse more than did oral drugs.”
BackgroundDefinitions and drivers of relapse in patients with schizophrenia: a systematic literature review
Olivares, J. M., Sermon, J., Hemels, M., & Schreiner, A. (2013) · Annals of General Psychiatry · doi:10.1186/1744-859x-12-32 · Cited by 270 · cited 3×
“…c, Henry A. Nasrallah d a Allergan, Inc., Jersey City, NJ, USA b Gedeon Richter Plc, Budapest, Hungary c Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, Innsbruck, Austria d Saint Louis University, St. Louis, MO, USA ⁎ Corresponding author at:…”
BackgroundSchizophrenia--Time to Commit to Policy Change
Fleischhacker, W. W., Arango, C., Arteel, P., Barnes, T. R. E., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S. R., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu006 · Cited by 214 · cited 1×
“…to clinical deterioration including worsening of symptoms, cognitive impairment, reduced social and vocational functioning, and diminished quality of life (Fleischhacker et al., 2014; Lehman et al., 2004; Olivares et al., 2013; Financial Center, Jersey City, NJ am). aithersburg, MD, USA.”
BackgroundSelf-citation
Research works printed but not linked: 27
- Arato, 2002, A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study, Int. Clin. Psychopharmacol., 17, 207, 10.1097/00004850-200209000-00001 · DOI · Paper page
- Axelrod, 1993, Validation of the 16-item Negative Symptom Assessment, J. Psychiatr. Res., 27, 253, 10.1016/0022-3956(93)90036-2 · DOI
- Barnes, 1989, A rating scale for drug-induced akathisia, Br. J. Psychiatry, 154, 672, 10.1192/bjp.154.5.672 · DOI · Paper page
- Beasley, 2003, A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse, J. Clin. Psychopharmacol., 23, 582, 10.1097/01.jcp.0000095348.32154.ec · DOI · Paper page
- Durgam, 2014, An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial, Schizophr. Res., 152, 450, 10.1016/j.schres.2013.11.041 · DOI · Paper page
- Durgam, 2015, Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase III randomized, double-blind, placebo- and active-controlled trial, J. Clin. Psychiatry, 76, e1574, 10.4088/JCP.15m09997 · DOI · Paper page
- Emsley, 2013, The nature of relapse in schizophrenia, BMC Psychiatry, 13, 50, 10.1186/1471-244X-13-50 · DOI · Paper page
- Graff-Guerrero, 2009, The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO, Arch. Gen. Psychiatry, 66, 606, 10.1001/archgenpsychiatry.2009.43 · DOI · Paper page
- Gyertyán, 2008, Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. Behavioural characterisation of RG-15, Naunyn Schmiedeberg's Arch. Pharmacol., 378, 529, 10.1007/s00210-008-0311-x · DOI
- Gyertyán, 2011, Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents, Neurochem. Int., 59, 925, 10.1016/j.neuint.2011.07.002 · DOI
- Kane, 2007, Treatment strategies to prevent relapse and encourage remission, J. Clin. Psychiatry, 68, 27
- Kane, 2011, A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment, J. Clin. Psychiatry, 72, 349, 10.4088/JCP.10m06306 · DOI · Paper page
- Kane, 2015, Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial, J. Clin. Psychopharmacol., 35, 1, 10.1097/JCP.0000000000000346 · DOI · Paper page
- Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr. Bull., 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
- Kiss, 2008, Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. Neurochemical characterisation of RG-15, Naunyn Schmiedeberg's Arch. Pharmacol., 378, 515, 10.1007/s00210-008-0308-5 · DOI
- Kiss, 2010, Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile, J. Pharmacol. Exp. Ther., 333, 328, 10.1124/jpet.109.160432 · DOI · Paper page
- Laszy, 2005, Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats, Psychopharmacology, 179, 567, 10.1007/s00213-004-2096-z · DOI
- Lehman, 2004, Practice guideline for the treatment of patients with schizophrenia, second edition, Am. J. Psychiatry, 161, 1
- Leucht, 2006, Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia, J. Clin. Psychiatry, 67, 3
- Mizrahi, 2011, Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO, Schizophr. Res., 131, 63, 10.1016/j.schres.2011.05.005 · DOI
- Morken, 2008, Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia, BMC Psychiatry, 8, 32, 10.1186/1471-244X-8-32 · DOI · Paper page
- Nakamura, 2016, Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment), Drug Des. Dev. Ther., 10, 327, 10.2147/DDDT.S95100 · DOI
- Pigott, 2003, Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study, J. Clin. Psychiatry, 64, 1048, 10.4088/JCP.v64n0910 · DOI · Paper page
- Schwartz, 2000, Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions, Brain Res. Brain Res. Rev., 31, 277, 10.1016/S0165-0173(99)00043-0 · DOI · Paper page
- Simpson, 1970, A rating scale for extrapyramidal side effects, Acta Psychiatr. Scand .Suppl., 212, 11, 10.1111/j.1600-0447.1970.tb02066.x · DOI · Paper page
- Taylor, 2009, Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review, Br. J. Psychiatry Suppl., 52, S13, 10.1192/bjp.195.52.s13 · DOI · Paper page
- Taylor, 2005, Towards consensus in the long-term management of relapse prevention in schizophrenia, Hum. Psychopharmacol., 20, 175, 10.1002/hup.675 · DOI · Paper page
Cited by
Ward, K., & Citrome, L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s169369 · Cited by 181
Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis
Speyer, H., Westergaard, C., Albert, N., Karlsen, M., Stürup, A. E., Nordentoft, M., & Krogh, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.577919 · Cited by 44
Weiss, C., Weiller, E., Baker, R. A., Duffy, R. A., Gwin, K. K., Zhang, P., & McQuade, R. D. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000226 · Cited by 28
Aigbogun, M. S., Liu, S., Kamat, S. A., Sapin, C., Duhig, A. M., & Citrome, L. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s160252 · Cited by 18
“The model evaluated a hypothetical cohort of adults with stable-phase schizophrenia consistently with patients enrolled in long-term prevention studies of brexpiprazole, 17 cariprazine, 20 and lurasidone.”
Metadata
- Authors
- Durgam, S., Earley, W., Li, R., Li, D., Lu, K., Laszlovszky, I., Fleischhacker, W. W., & Nasrallah, H. A.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 176
- Issue
- 2-3
- Pages
- 264-271
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2482680139
- Cited by
- 101
- References
- 7
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-02-01)
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.